Roche's Promising Weight-Loss Pill Shakes Up Obesity Drug Market
TL;DR Summary
Stocks of companies focused on obesity drugs, including Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics, fell on Wednesday following Roche's announcement of promising Phase 1 trial results for its obesity and type 2 diabetes drug, CT-996, which showed superior weight loss results compared to existing treatments.
- Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? Yahoo Finance
- Roche Climbs As Once-Daily Weight Loss Pill Shows Promise Forbes
- Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche CNBC
- Roche’s $2.7B weight-loss wager delivers early oral GLP-1 win Fierce Biotech
- A second Roche obesity drug shows promise in early studies STAT
Reading Insights
Total Reads
0
Unique Readers
15
Time Saved
2 min
vs 3 min read
Condensed
89%
434 → 48 words
Want the full story? Read the original article
Read on Yahoo Finance